Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SCNI 
Scinai Immunotherapeutics Ltd (SCNI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SCNI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $700
1 Year Target Price $700
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.06% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.53M USD | Price to earnings Ratio - | 1Y Target Price 700 |
Price to earnings Ratio - | 1Y Target Price 700 | ||
Volume (30-day avg) 1 | Beta 1.86 | 52 Weeks Range 1.40 - 4.76 | Updated Date 08/29/2025 |
52 Weeks Range 1.40 - 4.76 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 728.88% | Operating Margin (TTM) -1098.54% |
Management Effectiveness
Return on Assets (TTM) -34.92% | Return on Equity (TTM) 177.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7208881 | Price to Sales(TTM) 2.33 |
Enterprise Value 7208881 | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 10.96 | Enterprise Value to EBITDA 0.92 | Shares Outstanding 999919 | Shares Floating 2442673465 |
Shares Outstanding 999919 | Shares Floating 2442673465 | ||
Percent Insiders 18.22 | Percent Institutions 28.97 |
Upturn AI SWOT
Scinai Immunotherapeutics Ltd
Company Overview
History and Background
Scinai Immunotherapeutics Ltd. (SCII) is an Israeli biopharmaceutical company. Its history is marked by shifts in focus, originally specializing in medical devices manufacturing. It is now focused on developing innovative immunotherapies.
Core Business Areas
- Drug Development: Focused on the development of innovative immunotherapies. SCII is currently working on a few lead compounds including SCI-210, and SCI-110 for cancer treatment. They work on preclinical development, clinical trials, manufacturing, and commercialization.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other executives responsible for strategic direction, clinical development, and business operations. Details of organizational structure can be found on their website and annual reports.
Top Products and Market Share
Key Offerings
- SCI-210: This is an immunotherapy candidate targeting solid tumors. Currently in preclinical trials, details regarding market share are unavailable. Competitors include other companies with novel cancer therapies such as big pharma and biotech firms.
- SCI-110: This is also an immunotherapy candidate in development by Scinai. Currently in preclinical trials, details regarding market share are unavailable. Competitors include other companies with novel cancer therapies such as big pharma and biotech firms.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing with significant investments and innovations. This market is driven by technological advancements and the rise in cancer cases, as well as the demand for targeted and effective therapies.
Positioning
Scinai is a smaller player in the competitive immunotherapy space. Its competitive advantage lies in its focus on certain technology for immunotherapies.
Total Addressable Market (TAM)
The global immunotherapy market is estimated at hundreds of billions of dollars. Scinai's positioning is at the early stages of drug development, and they have yet to penetrate a large portion of this market.
Upturn SWOT Analysis
Strengths
- Innovative Immunotherapy Approach
- Experienced Management Team
- Pipeline of Drug Candidates
Weaknesses
- Limited Financial Resources
- Early Stage of Development
- Reliance on Partnerships
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Positive Clinical Trial Results
- Expansion into New Therapeutic Areas
Threats
- Competition from Established Players
- Regulatory Hurdles
- Clinical Trial Failures
- Funding risks
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- BMY
- JNJ
- GILD
Competitive Landscape
Scinai faces significant competition from established pharmaceutical companies with greater resources and broader product portfolios. Its success hinges on the uniqueness and effectiveness of its immunotherapy candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to its early stage of development and the lack of commercialized products.
Future Projections: Future growth is contingent on the success of its drug candidates in clinical trials and the ability to secure partnerships or funding.
Recent Initiatives: Recent initiatives include advancing clinical trials and exploring partnership opportunities.
Summary
Scinai Immunotherapeutics is a small biotech company focused on developing immunotherapies. Its success is heavily reliant on the success of its clinical trials and securing funding. Its small size makes it vulnerable in the competitive biotech landscape. However, success in clinical trials could be a massive payoff for investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a financial professional. The accuracy of the market share percentages are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scinai Immunotherapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-05-12 | CEO & Director Mr. Amir Reichman M.B.A., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.scinai.com |
Full time employees 31 | Website https://www.scinai.com | ||
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.